ImmunoScape Presents Data on Significant, Selective In-Vivo Expansion of Cell Therapy Product at AACR Annual Meeting

ImmunoScape Pte. Ltd., a spin-out of A*STAR backed by Amgen Ventures and EDBI that is developing next-generation TCR-based cancer immunotherapies, today announced the presentation of compelling new preclinical data at the American Association for Cancer Research (AACR) Annual Meeting 2026. The poster, titled “A novel ‘Seed-and-Boost’ immunotherapy drives potent TCR-T cell expansion, tumor infiltration, and durable tumor control,” was presented on Monday, April 20, 2026 by Michael Fehlings, PhD, Co-Founder and CEO of ImmunoScape.